GE HealthCare
(Nasdaq: GEHC)
unveiled its Signa Magnus head-only magnetic resonance (MR) scanner for neuroscience applications.
The FDA 510(k)-pending scanner could help explore advancements in neuroscience currently restricted by performance limitations of conventional whole-body MR systems. According to GE HealthCare, MRI can only diagnose a fraction of the world’s neurological disorders at present.
Signa Magnus signals the company’s effort to expand the neurological clinical applications of MRI. It features the company’s most advanced 3.0T MR imaging device specifically designed for neurological and oncological research purposes. The system offers superior gradient performance with its HyperG gradient technology as well. GE HealthCare says this enables the detection of fine details previously unattainable with MR.
Researchers can use the system’s capabilities to push the boundaries of advanced anatomical, diffusion and functional techniques. GE HealthCare said its own deep-learning algorithms amplify those capabilities. Additionally, many GE HealthCare 3.0T systems can be upgraded to Signa Magnus, helping customers save capital costs.
The company installed the investigational system in March at Brigham and Women’s Hospital. The company expects the leading hospital to collaborate on high-performance neuro MR research.
“With Signa Magnus, we are not just exploring the possibility of providing the tool; we are setting new benchmarks in medical research and future clinical patient care,” said Kelly Londy, GE HealthCare CEO of MR. “This innovation underscores our commitment to R&D and our collaborations with academia, pushing the boundaries of what’s possible in MR imaging. The potential impact of Signa Magnus on patient outcomes and our understanding of the human brain is profound.”
